News 07.01.2018 Molecular Partners AG announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners. Upon receipt of approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Molecular Partners will grant Allergan an exclusive license to the...
External events
Event date: 08.02.2018
Renaissance Zurich Tower Hotel, Turbinenstrasse 20, 8005 Zürich, Switzerland
Information about the event can be found in the flyer (and also on www.swissnordicbio.com). There you also have the promotion code which the Swiss companies can use when registering to get 50% off.
Agenda
News 09.11.2017 Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune...
Internal events
Event date: 22.01.2018
We are pleased to invite you to the first Life Science Zurich Impact conference on translational medicine, which is taking place on January 22, 2018 at the Technopark Zurich, Switzerland.
This one-day multi-track meeting is organised by the Life Science Zurich Business Network, the University of Zurich, the ETH, the Canton...
News 24.10.2017 Neurimmune announced today that it has raised $150 million to fund its growth strategy. The financing will accelerate the development of Neurimmune's human antibody pipeline through clinical proof of concept. Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously...